WallStSmart
FHTX

Foghorn Therapeutics Inc

NASDAQ: FHTX · HEALTHCARE · BIOTECHNOLOGY

$4.75
-0.21% today

Updated 2026-04-30

Market cap
$311.70M
P/E ratio
P/S ratio
10.08x
EPS (TTM)
$-1.18
Dividend yield
52W range
$3 – $7
Volume
0.2M

Foghorn Therapeutics Inc (FHTX) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
+0.2%
Last 4 quarters
Revenue YoY growth
+223.8%
Most recent quarter
EPS YoY growth
-21.8%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+7.6%
Last 2 reports
Positive reaction rate
100%
2 of 2 quarters
Largest single-day move
+13.3%
2025-11-05
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-05$-0.37-41.1%$5.67$5.78+1.9%
2025-11-05$-0.25+25.0%$3.53$4.00+13.3%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.26$-0.37-41.1%$9.25M+223.8%
2025-09-30$-0.33$-0.25+25.0%$8.15M+4.4%
2025-06-30$-0.35$-0.28+20.3%$7.56M+9.7%
2025-03-31$-0.29$-0.30-3.4%$5.95M+17.9%
2024-12-31$-0.29$-0.30-5.3%$2.86M-50.5%
2024-09-30$-0.44$-0.31+29.5%$7.81M-55.3%
2024-06-30$-0.65$-0.45+30.8%$6.89M+23.0%
2024-03-31$-0.63$-0.59+6.3%$5.05M-4.9%
2023-12-31$-0.76$-0.57+25.0%$5.77M
2023-09-30$-0.75$-0.34+54.7%$17.48M
2023-06-30$-0.73$-0.70+4.1%$5.60M
2023-03-31$-0.72$-0.73-1.4%$5.31M
2022-12-31$-0.62$-0.69-11.3%

Frequently asked questions

Has Foghorn Therapeutics Inc beaten earnings estimates?
Foghorn Therapeutics Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of +0.2% over the last 4 quarters.
How does FHTX stock react to earnings?
FHTX stock has moved an average of +7.6% in the trading day following earnings over its last 2 reports, with positive reactions in 100% of those quarters.
What is Foghorn Therapeutics Inc's revenue growth rate?
Foghorn Therapeutics Inc reported year-over-year revenue growth of +223.8% in its most recent quarter, with EPS growing -21.8% year-over-year.